EUVIMEDEUVIMED entdecken
Scoping Review

Reporting of participant race and ethnicity from COVID-19 randomized controlled drug and biologicals trials: a scoping review

Shelly Melissa Pranić iD, Maria Dulce Estevão iD, Lenny T Vasanthan iD, Iván Pérez-Neri iD, Anika Pulumati iD, Fábio Antonio Serra de Lima Junior iD, Narges Malih iD, Vinayak Mishra iD, Jacqueline Thompson iD, Daniel Nnate iD

Epidemiologic Reviews · 2025

DOI: 10.1093/epirev/mxae006 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Epidemiologic Reviews, 2025. Verfasst von Shelly Melissa Pranić und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, University of Split School of Medicine, 21000 Split, Croatia. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Randomized Controlled Trials as Topic, Ethnicity, Antiviral Agents. Die Arbeit nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Racial and ethnic minorities have been disproportionally burdened by hospitalization and death due to COVID-19. Participation of individuals of diverse races and ethnicities in clinical trials, according to study-level characteristics of randomized controlled trials (RCTs) that test effectiveness of COVID-19 drugs, could be insightful for future researchers. Our objective for this scoping review was to describe the frequency of race and ethnicity reported as demographic variables and specific reporting of race and ethnicity according to COVID-19 RCT characteristics. We conducted comprehensive searches in PubMed, ProQuest, World Health Organization Database, and Cochrane Central Register of Controlled Trials, and gray literature via preprint servers from January 1, 2020, to May 4, 2022. We included RCTs on emergency- or conditionally approved COVID-19 drug interventions (remdesivir, baricitinib, and molnupiravir) with or without comparators. Self-reported race as American Indian/Pacific Islander, Asian, Black/African American, or White, ethnicity as Hispanic/Latinx, study design characteristics, and participant-relevant data were collected. In total, 17 RCTs with 17 935 participants were included. Most (n = 13; 76%) reported at least 1 race and ethnicity and were US-based, industry-funded RCTs. Asian, Black, Latinx, and White participants were mostly enrolled in RCTs that studied remdesivir. Native American and Hawaiian participants were mostly assessed for progression to high-flow oxygen/noninvasive ventilation. Time to recovery was assessed predominantly in Black and White participants, whereas hospitalization or death was mostly assessed in Asian, Latinx, and multirace participants. Trialists should be aware of RCT-level factors and characteristics that may be associated with low participation of racial and ethnic minorities, which could inform evidence-based interventions to increase minority participation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentRandomized Controlled Trials as TopicEthnicityAntiviral AgentsRacial GroupsCOVID-19Biological ProductsHumansAdenosine MonophosphateAlaninePurinesSulfonamidesAzetidinesSARS-CoV-2PyrazolesCytidineHydroxylamines

Stichwörter der Autor:innen

COVID-19ethnicityracerandomized controlled trialtherapeutics

Substanzen

Antiviral AgentsAdenosine MonophosphateAlanineremdesivirPurinesSulfonamidesAzetidinesbaricitinibBiological Productsmolnupiravir

Autor:innen und Institutionen

  • Department of Public Health, University of Split School of Medicine, 21000 Split, Croatia.
  • Cochrane Croatia, 21000 Split, Croatia.
  • School of Health, University of Algarve, Faro, Faro District, 8005-139, Portugal.
  • Physiotherapy Unit, Physical Medicine and Rehabilitation Department, Christian Medical College, Vellore, 632004, India.
  • Department of Neurochemistry, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Insurgentes Sur 3877, La Fama, Tlalpan, 14269, Ciudad de México, Mexico.
  • University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States.

ORCID-Profile: Shelly Melissa Pranić, Maria Dulce Estevão, Lenny T Vasanthan, Iván Pérez-Neri, Anika Pulumati, Fábio Antonio Serra de Lima Junior, Narges Malih, Vinayak Mishra, Jacqueline Thompson, Daniel Nnate

Zitieren

APA

Pranić, S. M., Estevão, M. D., Vasanthan, L. T., Pérez-Neri, I., Pulumati, A., de Lima Junior, F. A. S., Malih, N., Mishra, V., Thompson, J., & Nnate, D. (2025). Reporting of participant race and ethnicity from COVID-19 randomized controlled drug and biologicals trials: a scoping review. Epidemiologic Reviews. https://doi.org/10.1093/epirev/mxae006

Vancouver

Pranić SM, Estevão MD, Vasanthan LT, Pérez-Neri I, Pulumati A, de Lima Junior FAS, et al. Reporting of participant race and ethnicity from COVID-19 randomized controlled drug and biologicals trials: a scoping review. Epidemiologic Reviews. 2025. doi:10.1093/epirev/mxae006

BibTeX
@article{Prani2025,
  author = {Pranić, Shelly Melissa and Estevão, Maria Dulce and Vasanthan, Lenny T and Pérez-Neri, Iván and Pulumati, Anika and de Lima Junior, Fábio Antonio Serra and Malih, Narges and Mishra, Vinayak and Thompson, Jacqueline and Nnate, Daniel},
  title = {Reporting of participant race and ethnicity from COVID-19 randomized controlled drug and biologicals trials: a scoping review},
  journal = {Epidemiologic Reviews},
  year = {2025},
  doi = {10.1093/epirev/mxae006}
}
Kostenlos starten →